- Vaccines
- Monoclonal Antibodies
Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market is poised to grow at a CAGR of 27.1% from 2024 to 2030. RSV is a major cause of lower respiratory tract infections, particularly severe in infants, older adults, and immunocompromised individuals. Globally, RSV causes an estimated 33 million cases of acute lower respiratory infection in children under 5 years annually, resulting in more than 3 million hospitalizations and about 60,000 in-hospital deaths in children under 5 years. The increasing recognition of RSV's significant health and economic burden drives the market for vaccines and antibodies. Additionally, the COVID-19 pandemic has heightened awareness about respiratory viruses, accelerating research and development in this field.
Technological advancements, including the application of mRNA technology and structure-based vaccine design, contribute to market growth by improving vaccine efficacy and production efficiency. Recent breakthroughs in understanding RSV's molecular structure and immune responses have reinvigorated the field after previous setbacks. However, challenges such as the virus's ability to evade immune responses and the need for different approaches for various age groups may impact market dynamics. Stringent regulatory requirements, given past vaccine-enhanced disease incidents, also influence development timelines and market entry. North America held the largest market share in 2023 and is expected to maintain its dominance in the forecast period, driven by robust research infrastructure and high healthcare expenditure.
In August 2023, Pfizer received additional FDA approval for ABRYSVO, their RSV vaccine. This development:
In July 2023, Pfizer received FDA approval for ABRYSVO, their RSV vaccine for older adults. This development:
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The high disease burden of RSV, especially in vulnerable populations, is a primary driver for market growth. RSV is responsible for substantial healthcare costs, with annual US hospitalization costs for infants estimated at $650 million. The potential for vaccines and antibodies to significantly reduce this burden is fueling investment and research. Advancements in vaccine technology, including mRNA platforms and structure-based antigen design, have overcome previous obstacles in RSV vaccine development. These innovations allow for more precise targeting of RSV's fusion (F) protein, a key component for viral entry into host cells. The market is also benefiting from increased government and private funding for vaccine development, particularly following the COVID-19 pandemic. However, challenges remain, including the need to develop safe and effective products for diverse age groups and the complexity of conducting large-scale clinical trials in pediatric populations. Regulatory scrutiny is high due to historical incidents of vaccine-enhanced disease in RSV vaccine trials, necessitating extensive safety data. This scrutiny, while ensuring product safety, can extend development timelines and increase costs.
Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market is expected to grow at a CAGR of 27.1% from 2024 to 2030.
The Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market is segmented based on Product Type, Target Population, Clinical Trial Phase, and Geography.
The leading players in the global Respiratory Syncytial Virus (RSV) Vaccine and Antibody Pipeline Market are GSK, Pfizer, Moderna, AstraZeneca, Sanofi, Janssen (Johnson & Johnson), Novavax, Bavarian Nordic, Merck, and Codagenix.
Historic years considered for the market study are 2019-2022, 2023 is considered as the base year for market estimation, and Seven years forecast is presented from 2024 – 2030.
1.Executive Summary |
2.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market Introduction |
2.1.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market - Taxonomy |
2.2.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market - Definitions |
2.2.1. Product |
2.2.2.Target Population |
2.2.3.Clinical Trial Phase |
2.2.4.Region |
3.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market By Product, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Vaccines |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Monoclonal Antibodies |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market By Target Population, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Infants |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Older Adults |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Pregnant Women |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
7.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market By Clinical Trial Phase, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Phase I |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Phase II |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Phase III |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Vaccines |
9.1.2.Monoclonal Antibodies |
9.2. Target Population Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Infants |
9.2.2.Older Adults |
9.2.3.Pregnant Women |
9.3. Clinical Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Phase I |
9.3.2.Phase II |
9.3.3.Phase III |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Vaccines |
10.1.2.Monoclonal Antibodies |
10.2. Target Population Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Infants |
10.2.2.Older Adults |
10.2.3.Pregnant Women |
10.3. Clinical Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Phase I |
10.3.2.Phase II |
10.3.3.Phase III |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Vaccines |
11.1.2.Monoclonal Antibodies |
11.2. Target Population Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Infants |
11.2.2.Older Adults |
11.2.3.Pregnant Women |
11.3. Clinical Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Phase I |
11.3.2.Phase II |
11.3.3.Phase III |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Vaccines |
12.1.2.Monoclonal Antibodies |
12.2. Target Population Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Infants |
12.2.2.Older Adults |
12.2.3.Pregnant Women |
12.3. Clinical Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Phase I |
12.3.2.Phase II |
12.3.3.Phase III |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Respiratory Syncytial Virus Vaccine and Antibody Pipeline Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Product Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Vaccines |
13.1.2.Monoclonal Antibodies |
13.2. Target Population Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Infants |
13.2.2.Older Adults |
13.2.3.Pregnant Women |
13.3. Clinical Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Phase I |
13.3.2.Phase II |
13.3.3.Phase III |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.GSK |
14.2.2.Pfizer |
14.2.3.Moderna |
14.2.4.AstraZeneca |
14.2.5.Sanofi |
14.2.6.Janssen (Johnson & Johnson) |
14.2.7.Novavax |
14.2.8.Bavarian Nordic |
14.2.9.Merck |
14.2.10.Codagenix |
14.2.11.Meissa Vaccines |
14.2.12.Icosavax |
15. Research Methodology |
16. Appendix and Abbreviations |